William D. Figg
National Institutes of Health(US)National Cancer Institute(UA)National Cancer Institute(MY)National Cancer Institute(US)Center for Cancer Research(US)National Institutes of Health Clinical Center(US)Spanish Oncology Genitourinary Group(ES)University of Colorado Anschutz Medical Campus(US)University of Colorado Denver(US)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer Treatment and Pharmacology, Multiple Myeloma Research and Treatments, Cancer Immunotherapy and Biomarkers, Protein Degradation and Inhibitors
Most-Cited Works
- → Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group(1999)982 cited
- → Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma(2016)807 cited
- → Antibody–drug conjugates for cancer(2019)761 cited
- → Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma(2009)731 cited
- → Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer(2014)691 cited
- → Selumetinib in Children with Inoperable Plexiform Neurofibromas(2020)667 cited